Breaking News

Improve Your Cell Viability with INTEGRA Liquid Handling Solutions

This equipment is designed to offer enhanced pipetting speed control, limiting the stress placed on cells during handling to improve cell viability.

Unicycive Therapeutics to be Added to Russell Microcap® Index

Company is scheduled to be added as a member of the Russell Microcap® Index as part of the 2021 Russell indexes reconstitution after the market opens on September 20, 2021, based on a preliminary list of additions.

BioInnovation Institute Launches Venture Lab Program with Intake of Innovative Early-stage Companies

BII’s Venture Lab program offers a platform for bringing ground-breaking science and research ideas to life and will be instrumental in enabling scientists and entrepreneurs to tap into a wealth of expertise and support.

New Acquisitions & Mergers

Enveric Biosciences Announces Closing of MagicMed Industries Acquisition

Enveric intends to immediately accelerate the development of a novel Psychedelic molecule for Cancer Related Distress.

Insightful Science Acquires FCS Express

FCS Express expands the flow cytometry solutions within the Insightful Science platform, enabling world-class data-driven scientific research in academia and biopharma and clinical analysis in regulated enterprise environments. Insightful Science is the leading end-to-end scientific research platform with both the broadest and deepest scientific capabilities across chemistry and biology. The unique platform accelerates innovation and drug discovery by producing a seamless flow of clean and trustworthy data throughout labs.

Growth / Development

54gene Closes $25M Series B

The round also included participation from Adjuvant Capital, KdT Ventures, Plexo Capital, Endeavor Capital, Ingressive Capital and others.

Vanqua Bio Launches with $85 Million Series B Financing and a Mission to Vanquish Neurodegenerative Diseases

Novel drug-development approach combines advanced insights into critical neuronal cell pathways with cutting-edge assays to enable next-generation therapies.

Clinical Trials

1st Patient Receives Low-dose Psilocybin in World 1st Clinical Trial for Rare Headache Disorder

World-first phase 1 trial will evaluate efficacy of psilocybin in Short-lasting Unilateral Neuralgiform Headache Attacks (SUNHA). Data expected in early 2022. SUNHA, a rare and debilitating headache condition, is estimated to affect 40,000 patients in US and Europe.

Strata Oncology Announces Publication of Analytical and Clinical Validation of StrataNGS® in the Journal of Molecular Diagnostics

"StrataNGS demonstrated the sensitivity and specificity required for routine clinical practice while reporting all CGP variant classes from minute FFPE tissue samples," said Scott Tomlins, M.D., Ph.D., co-founder and Chief Medical Officer, Strata Oncology.

Executives on the Move

Camilla Soenderby Appointed to F2G Board of Directors

Francesco Maria Lavino, CEO of F2G Ltd, added: "Camilla's experience and successful track record in rare diseases will be invaluable as we look to maximise the potential of olorofim.

Cumulus Neuroscience Appoints Dr. Ruth McKernan CBE as Chair

Ruth McKernan, newly appointed Chair added: “The formation of Cumulus Neuroscience represents a significant opportunity to address some of the current limitations of clinical trials in dementia and other brain disorders.

Jennifer Herron, of ADC Therapeutics, Joins Genocea Biosciences’ Board of Directors

Chip Clark, Genocea’s President, and Chief Executive Officer said, "As we advance our pipeline, including GEN-011, our neoantigen-targeted T cell therapy for the treatment of solid tumors, we believe Jennifer’s deep industry and commercial expertise will prove invaluable to us."

FDA Cleared Devices & News

Co-Diagnostics JV CoSara Receives Clearance from Indian FDA for Chikungunya and Dengue Tests

The Saragene test kits approved by the CDSCO use the Company's patented CoPrimer™ technology for the qualitative detection of these mosquito-borne viruses.

FDA Clears Promega OncoMate™ MSI Dx Analysis System

Oncologists and pathologists in US can now use microsatellite instability (MSI) diagnostic to screen for Lynch syndrome in patients with colorectal cancer.

Pharma

Biophytis Announces DMC Second Interim Analysis Efficacy Results in the Promising Zone Allowing Continuation of Phase 2/3 COVA Study With Sarconeos (BIO101) in COVID-19

The second Interim Analysis based on 155 hospitalized patients shows no futility, with efficacy results in the promising zone, indicating that BIO101 remains a candidate treatment for acute respiratory failure associated with COVID-19.

AbbVie, Eisai, and EA Pharma Launch “Humira Support Tool Ordering Service for Patients”

"Humira Support Tool Ordering Service for Patients" is a free-of-charge service that assists patients on Humira therapy by directly delivering support tools to their home or other requested location.